Cargando…
Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer
BACKGROUND: The study was designed to evaluate the potential validity and utility of selected molecular markers in serum samples from patients with specific stages of laryngeal intraepithelial lesions that could serve as diagnostic tools in differentiation of benign and dysplastic lesions from invas...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029362/ https://www.ncbi.nlm.nih.gov/pubmed/35462765 http://dx.doi.org/10.7717/peerj.13104 |
_version_ | 1784691859223740416 |
---|---|
author | Żurek, Michał Rzepakowska, Anna Kotuła, Iwona Demkow, Urszula Niemczyk, Kazimierz |
author_facet | Żurek, Michał Rzepakowska, Anna Kotuła, Iwona Demkow, Urszula Niemczyk, Kazimierz |
author_sort | Żurek, Michał |
collection | PubMed |
description | BACKGROUND: The study was designed to evaluate the potential validity and utility of selected molecular markers in serum samples from patients with specific stages of laryngeal intraepithelial lesions that could serve as diagnostic tools in differentiation of benign and dysplastic lesions from invasive pathologies. METHODS: Prospective study included 80 consecutive patients with vocal fold lesions treated at the single otorhinolaryngology centre. All participants had surgical resection of the lesion. Blood samples were collected from each patient before the surgery. Final diagnosis was confirmed on histopathological examination and included 39 (48.75%) non-dysplastic lesions, eight (10%) low-grade dysplasia, six (7.5%) high-grade dysplasia and 27 (33.75%) invasive cancers. The ELISA procedures were performed according to the manufacturer’s instruction. Individual serum concentration of selected proteins was reported in ng/ml: Vascular Endothelial-Cadherin Complex (VE-cad), CD44, Human High mobility group protein B1(HMGB1), Kallikrein 6. RESULTS: The highest mean levels of HMGB1, KLK6 and VE-cad were detected in sera of patients with low-grade dysplasia (81.14, 24.33, 14.17 respectively). Soluble CD44 was the most elevated in patients with non-dysplastic lesions (2.49). The HMGB1, KLK6 and VE-cad serum levels were increasing from non-dysplastic to low-grade dysplasia and followed by the decrease for high-grade dysplasia and invasive cancer, however the differences were not significant (p-values 0.897, 0.354, 0.1 respectively). Patients’ serum had the highest CD44 concentration in non-dysplastic and low-grade dysplasia with the following decrease through high-grade dysplasia and invasive cancer. GERD symptomatic patients had higher levels of KLK6 and CD44 than other patients (p-value 0.06 and 0.084 respectively). There were no significant differences of biomarkers levels related to patients’ gender (p-value from 0.243 to 1) or smoking status (p-value from 0.22 to 0.706). CONCLUSIONS: VE-cad, HMGB1, CD44 and KLK6 did not prove to be reliable biomarkers implicating malignant potential within vocal fold hypertrophic intraepithelial lesions. |
format | Online Article Text |
id | pubmed-9029362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | PeerJ Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90293622022-04-23 Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer Żurek, Michał Rzepakowska, Anna Kotuła, Iwona Demkow, Urszula Niemczyk, Kazimierz PeerJ Hematology BACKGROUND: The study was designed to evaluate the potential validity and utility of selected molecular markers in serum samples from patients with specific stages of laryngeal intraepithelial lesions that could serve as diagnostic tools in differentiation of benign and dysplastic lesions from invasive pathologies. METHODS: Prospective study included 80 consecutive patients with vocal fold lesions treated at the single otorhinolaryngology centre. All participants had surgical resection of the lesion. Blood samples were collected from each patient before the surgery. Final diagnosis was confirmed on histopathological examination and included 39 (48.75%) non-dysplastic lesions, eight (10%) low-grade dysplasia, six (7.5%) high-grade dysplasia and 27 (33.75%) invasive cancers. The ELISA procedures were performed according to the manufacturer’s instruction. Individual serum concentration of selected proteins was reported in ng/ml: Vascular Endothelial-Cadherin Complex (VE-cad), CD44, Human High mobility group protein B1(HMGB1), Kallikrein 6. RESULTS: The highest mean levels of HMGB1, KLK6 and VE-cad were detected in sera of patients with low-grade dysplasia (81.14, 24.33, 14.17 respectively). Soluble CD44 was the most elevated in patients with non-dysplastic lesions (2.49). The HMGB1, KLK6 and VE-cad serum levels were increasing from non-dysplastic to low-grade dysplasia and followed by the decrease for high-grade dysplasia and invasive cancer, however the differences were not significant (p-values 0.897, 0.354, 0.1 respectively). Patients’ serum had the highest CD44 concentration in non-dysplastic and low-grade dysplasia with the following decrease through high-grade dysplasia and invasive cancer. GERD symptomatic patients had higher levels of KLK6 and CD44 than other patients (p-value 0.06 and 0.084 respectively). There were no significant differences of biomarkers levels related to patients’ gender (p-value from 0.243 to 1) or smoking status (p-value from 0.22 to 0.706). CONCLUSIONS: VE-cad, HMGB1, CD44 and KLK6 did not prove to be reliable biomarkers implicating malignant potential within vocal fold hypertrophic intraepithelial lesions. PeerJ Inc. 2022-04-19 /pmc/articles/PMC9029362/ /pubmed/35462765 http://dx.doi.org/10.7717/peerj.13104 Text en © 2022 Żurek et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
spellingShingle | Hematology Żurek, Michał Rzepakowska, Anna Kotuła, Iwona Demkow, Urszula Niemczyk, Kazimierz Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer |
title | Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer |
title_full | Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer |
title_fullStr | Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer |
title_full_unstemmed | Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer |
title_short | Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer |
title_sort | serum expression of vascular endothelial-cadherin, cd44, human high mobility group b1, kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer |
topic | Hematology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029362/ https://www.ncbi.nlm.nih.gov/pubmed/35462765 http://dx.doi.org/10.7717/peerj.13104 |
work_keys_str_mv | AT zurekmichał serumexpressionofvascularendothelialcadherincd44humanhighmobilitygroupb1kallikrein6proteinsindifferentstagesoflaryngealintraepitheliallesionsandearlyglottiscancer AT rzepakowskaanna serumexpressionofvascularendothelialcadherincd44humanhighmobilitygroupb1kallikrein6proteinsindifferentstagesoflaryngealintraepitheliallesionsandearlyglottiscancer AT kotułaiwona serumexpressionofvascularendothelialcadherincd44humanhighmobilitygroupb1kallikrein6proteinsindifferentstagesoflaryngealintraepitheliallesionsandearlyglottiscancer AT demkowurszula serumexpressionofvascularendothelialcadherincd44humanhighmobilitygroupb1kallikrein6proteinsindifferentstagesoflaryngealintraepitheliallesionsandearlyglottiscancer AT niemczykkazimierz serumexpressionofvascularendothelialcadherincd44humanhighmobilitygroupb1kallikrein6proteinsindifferentstagesoflaryngealintraepitheliallesionsandearlyglottiscancer |